Table 1.
Gardasil | Cervarix | |
---|---|---|
Proper name | HPV quadrivalent (types 6, 11, 16, 18) vaccine, recombinant | HPV bivalent (types 16 and 18) vaccine, recombinant |
Manufacturer | Merck & Co. | GlaxoSmithKline Biologicals |
VLP types | 6, 11, 16, 18 | 16, 18 |
Adjuvant | 225 µg aluminum hydroxyphosphate sulfate | 500 µg aluminum hydroxide, 50 µg3-O-deacylated-4′-monophosphoryl lipid A |
Schedule | 0, 2, 6 mo | 0, 1, 6 mo |
Indications | Vaccination in females between 9 and 26 y of age for prevention of diseases caused by HPV 6/11/16/18: Cervical cancer Genital warts Cervical adenocarcinoma in situ (AIS) Cervical intraepithelial neoplasia (CIN) grades 1, 2, and 3 Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3 Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3 Prevention of vulvar and vaginal cancer Vaccination in boys and men between 9 and 26 y of age for the prevention of genital warts caused by HPV 6/11 Vaccination in people aged 9 to 26 y for the prevention of anal cancer and associated precancerous lesions caused by HPV 6/11/16/18 |
Vaccination in females between 9 and 25 y of age for the prevention of disease caused by HPV 16/18: Cervical cancer CIN grades 1, 2, and 3 AIS |
Data from FDA-approved indications for Gardasil. Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM094042. Accessed December 10, 2012; and FDA-approved indications for Cervarix. Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM094042. Accessed December 10, 2012.